FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044336467> ?p ?o ?g. }

• W3044336467 endingPage "175883592095019" @default.
• W3044336467 startingPage "175883592095019" @default.
• W3044336467 abstract "Immune checkpoint inhibitors (ICIs) are effective for advanced renal-cell carcinoma (aRCC) but can increase costs. This study compares the efficacy, safety and cost-effectiveness of ICIs for newly diagnosed aRCC patients in the first-line setting.Trials evaluating ICI regimens as first-line treatment for newly diagnosed aRCC were searched and included. A network meta-analysis (NMA) was conducted, and a cost-effectiveness analysis was performed from the US payer's perspective. The key outcomes were overall survival (OS) and progression-free survival (PFS) in the NMA, and quality-adjusted life years (QALYs), costs and the incremental cost-effectiveness ratio (ICER) in the cost-effectiveness analysis.Four randomized controlled trials (RCTs) involving 3758 patients receiving first-line ICIs treatment were analyzed. The NMA showed that pembrolizumab plus axitinib was ranked higher than the other three ICI regimens and sunitinib in the overall population. Nivolumab plus ipilimumab and pembrolizumab plus axitinib achieved more health benefits than the other ICI regimens and sunitinib in programmed death ligand 1 (PD-L1)-positive and negative tumors, respectively. Among the four ICI regimens, only the ICERs of nivolumab plus ipilimumab over sunitinib were lower than the willingness-to-pay threshold ($150,000/QALY) in the overall and PD-L1-positive populations, and none of four ICI regimens were lower than $150,000/QALY in PD-L1-negative populations.The NMA and cost-effectiveness analysis revealed that nivolumab plus ipilimumab is the most favorable first-line treatment for PD-L1-positive aRCC compared with other ICI regimens and sunitinib. Pembrolizumab plus axitinib is likely to be an alternative for PD-L1-negative aRCC due to its more favorable health advantages." @default.
• W3044336467 created "2020-07-29" @default.
• W3044336467 creator A5001888280 @default.
• W3044336467 creator A5003515419 @default.
• W3044336467 creator A5047040073 @default.
• W3044336467 creator A5072236632 @default.
• W3044336467 date "2020-01-01" @default.
• W3044336467 modified "2023-10-14" @default.
• W3044336467 title "First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis" @default.
• W3044336467 cites W1570088421 @default.
• W3044336467 cites W1823658262 @default.
• W3044336467 cites W1985943243 @default.
• W3044336467 cites W2009138599 @default.
• W3044336467 cites W2068411642 @default.
• W3044336467 cites W2075535893 @default.
• W3044336467 cites W2080477888 @default.
• W3044336467 cites W2082351949 @default.
• W3044336467 cites W2100722947 @default.
• W3044336467 cites W2111999709 @default.
• W3044336467 cites W2254412226 @default.
• W3044336467 cites W2289315414 @default.
• W3044336467 cites W23165408 @default.
• W3044336467 cites W2513374664 @default.
• W3044336467 cites W2560219063 @default.
• W3044336467 cites W2572174216 @default.
• W3044336467 cites W2597355988 @default.
• W3044336467 cites W2612327959 @default.
• W3044336467 cites W2749428689 @default.
• W3044336467 cites W2751792491 @default.
• W3044336467 cites W2752568644 @default.
• W3044336467 cites W2755525655 @default.
• W3044336467 cites W2790729376 @default.
• W3044336467 cites W2791442381 @default.
• W3044336467 cites W2791483720 @default.
• W3044336467 cites W2792937256 @default.
• W3044336467 cites W2796140875 @default.
• W3044336467 cites W2886688315 @default.
• W3044336467 cites W2898662678 @default.
• W3044336467 cites W2911812451 @default.
• W3044336467 cites W2913745075 @default.
• W3044336467 cites W2921196841 @default.
• W3044336467 cites W2943887705 @default.
• W3044336467 doi "https://doi.org/10.1177/1758835920950199" @default.
• W3044336467 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7436799" @default.
• W3044336467 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32874210" @default.
• W3044336467 hasPublicationYear "2020" @default.
• W3044336467 type Work @default.
• W3044336467 sameAs 3044336467 @default.
• W3044336467 citedByCount "19" @default.
• W3044336467 countsByYear W30443364672021 @default.
• W3044336467 countsByYear W30443364672022 @default.
• W3044336467 countsByYear W30443364672023 @default.
• W3044336467 crossrefType "journal-article" @default.
• W3044336467 hasAuthorship W3044336467A5001888280 @default.
• W3044336467 hasAuthorship W3044336467A5003515419 @default.
• W3044336467 hasAuthorship W3044336467A5047040073 @default.
• W3044336467 hasAuthorship W3044336467A5072236632 @default.
• W3044336467 hasBestOaLocation W30443364671 @default.
• W3044336467 hasConcept C121608353 @default.
• W3044336467 hasConcept C126322002 @default.
• W3044336467 hasConcept C143998085 @default.
• W3044336467 hasConcept C2776539811 @default.
• W3044336467 hasConcept C2777472916 @default.
• W3044336467 hasConcept C2777701055 @default.
• W3044336467 hasConcept C2779490328 @default.
• W3044336467 hasConcept C2780030458 @default.
• W3044336467 hasConcept C2780057760 @default.
• W3044336467 hasConcept C2781433595 @default.
• W3044336467 hasConcept C2908647359 @default.
• W3044336467 hasConcept C71924100 @default.
• W3044336467 hasConcept C95190672 @default.
• W3044336467 hasConcept C99454951 @default.
• W3044336467 hasConceptScore W3044336467C121608353 @default.
• W3044336467 hasConceptScore W3044336467C126322002 @default.
• W3044336467 hasConceptScore W3044336467C143998085 @default.
• W3044336467 hasConceptScore W3044336467C2776539811 @default.
• W3044336467 hasConceptScore W3044336467C2777472916 @default.
• W3044336467 hasConceptScore W3044336467C2777701055 @default.
• W3044336467 hasConceptScore W3044336467C2779490328 @default.
• W3044336467 hasConceptScore W3044336467C2780030458 @default.
• W3044336467 hasConceptScore W3044336467C2780057760 @default.
• W3044336467 hasConceptScore W3044336467C2781433595 @default.
• W3044336467 hasConceptScore W3044336467C2908647359 @default.
• W3044336467 hasConceptScore W3044336467C71924100 @default.
• W3044336467 hasConceptScore W3044336467C95190672 @default.
• W3044336467 hasConceptScore W3044336467C99454951 @default.
• W3044336467 hasLocation W30443364671 @default.
• W3044336467 hasLocation W30443364672 @default.
• W3044336467 hasLocation W30443364673 @default.
• W3044336467 hasOpenAccess W3044336467 @default.
• W3044336467 hasPrimaryLocation W30443364671 @default.
• W3044336467 hasRelatedWork W3027525046 @default.
• W3044336467 hasRelatedWork W3056885861 @default.
• W3044336467 hasRelatedWork W3080692347 @default.
• W3044336467 hasRelatedWork W3086501416 @default.
• W3044336467 hasRelatedWork W3092591340 @default.
• W3044336467 hasRelatedWork W3127167392 @default.
• W3044336467 hasRelatedWork W3211505627 @default.

• next